GP BULLETIN: A NEWSLETTER FOR GPs BY HEALTHWAY MEDICAL



MANAGEMENT OF GASTROESOPHAGEAL AND EXTRA-ESOPHAGEAL REFLUX DISEASE

Dr Wang Yu Tien

MBBS (Sydney), MRCP (UK) Consultant Hepatologist and Gastroenterologist, Nobel Gastroenterology Centre Gleneagles Medical Centre

Proton Pump Inhibitors (PPIs) are the mainstay of management of gastroesophageal reflux disease (GERD). However, 10-40% of patients with GERD are non-responsive to PPI therapy.¹





Key messages:

- Lifestyle modifications play an important role in treatment of patients with reflux associated symptoms.²
- Treatment options for PPI unresponsive GERD include surgical, endoscopic, pharmacology and psychologic therapies.¹

References

1. Yadlapati R, Vaezi MF, Vela MF, et al. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. *Am J Gastroenterol.* 2018 Jul;113(7):980; 2. Gillson S. How heartburn is treated. [Internet] Available at: https://www.verywellhealth.com/heartburn-treatments-1742754. Accessed 28 May, 2021; 3. Vaezi MF, Katzka D, Zerbib F. Extraesophageal symptoms and diseases attributed to GERD: where is the pendulum swinging now?. *Clin Gastroenterol Hepatol.* 2018 Jul 1;16(7):1018-29.

Strictly for health care professionals only. Full prescribing information is available upon request.

Disclaimer

This event is owned, managed and hosted by Healthway Medical Group. Viatris supports the program through an educational grant and only aids in communicating the same. Viatris will not be held responsible and liable for the content and/or views shared through this program.

Made possible by an independent grant from Viatris Singapore



Pfizer PFE Private Limited (A Viatris Company) 80 Pasir Panjang Road, #17-83, Mapletree Business City, Singapore 117372 Organised by Healthway Medical

